Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Socazolimab combined with albumin-bound paclitaxel in advanced urothelial carcinoma
NCT04603846Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of socazolimab in urothelial carcinoma (UC), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoints: Dose limiting toxicity at 21 days and Recommended phase II dose at 21 days. Status: unknown.
02
Drugs
socazolimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04603846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603846.